Compare Stocks: TELO, VOR, ABOS, and STRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$0.21 -90.8%	$2.41	$0.21 ▼ $3.60	$165.63M	0.33	709,301 shs	66.37 million shs
STRO Sutro Biopharma	$9.10 -0.4%	$15.39	$7.15 ▼ $43.85	$151.55M	1.49	360,277 shs	122,290 shs
TELO Telomir Pharmaceuticals	$0.94 -3.0%	$1.13	$0.79 ▼ $1.58	$71.04M	-0.31	133,096 shs	96,698 shs
VOR Vor Biopharma	$19.68 -5.9%	$20.75	$6.50 ▼ $26.76	$1.24B	1.78	807,446 shs	759,594 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-3.78%	+11.17%	+2.23%	+6.51%	+1.33%
STRO Sutro Biopharma	-1.61%	-11.18%	-43.23%	-62.18%	-12.95%
TELO Telomir Pharmaceuticals	-4.53%	-4.53%	-17.59%	-20.31%	-35.72%
VOR Vor Biopharma	+1.26%	+10.40%	+14.08%	-1.13%	-18.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$0.21 -90.8%	$2.41	$0.21 ▼ $3.60	$165.63M	0.33	709,301 shs	66.37 million shs
STRO Sutro Biopharma	$9.10 -0.4%	$15.39	$7.15 ▼ $43.85	$151.55M	1.49	360,277 shs	122,290 shs
TELO Telomir Pharmaceuticals	$0.94 -3.0%	$1.13	$0.79 ▼ $1.58	$71.04M	-0.31	133,096 shs	96,698 shs
VOR Vor Biopharma	$19.68 -5.9%	$20.75	$6.50 ▼ $26.76	$1.24B	1.78	807,446 shs	759,594 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-3.78%	+11.17%	+2.23%	+6.51%	+1.33%
STRO Sutro Biopharma	-1.61%	-11.18%	-43.23%	-62.18%	-12.95%
TELO Telomir Pharmaceuticals	-4.53%	-4.53%	-17.59%	-20.31%	-35.72%
VOR Vor Biopharma	+1.26%	+10.40%	+14.08%	-1.13%	-18.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.33	Hold	$4.50	2,042.86% Upside
STRO Sutro Biopharma	3.00	Buy	$49.50	443.96% Upside
TELO Telomir Pharmaceuticals	2.25	Hold	$4.00	327.72% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$38.00	93.09% Upside

Current Analyst Ratings Breakdown

Latest TELO, VOR, ABOS, and STRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
10/30/2026	ABOS Acumen Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$1.00
10/21/2026	VOR Vor Biopharma	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/19/2026	STRO Sutro Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/16/2026	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/15/2026	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$60.00
10/15/2026	VOR Vor Biopharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	STRO Sutro Biopharma	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$49.00
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$4.00

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$0.48 per share	N/A
STRO Sutro Biopharma	$45.70M	3.30	N/A	N/A	($15.43) per share	-0.59
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.54	N/A	N/A	N/A	N/A	-166.49%	-90.79%	N/A
STRO Sutro Biopharma	-$191.09M	-$11.97	N/A	N/A	N/A	-395.25%	N/A	-88.12%	11/5/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	12/2/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TELO, VOR, ABOS, and STRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	STRO Sutro Biopharma	-$1.6637	N/A	N/A	N/A	$13.61 million	N/A
10/30/2026	Q3 2026	VOR Vor Biopharma	-$0.81	-$1.45	-$0.64	-$1.45	N/A	N/A
10/26/2026	Q3 2026	ABOS Acumen Pharmaceuticals	-$0.3886	-$0.35	+$0.0386	-$0.35	N/A	N/A
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/12/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/12/2026	Q2 2026	STRO Sutro Biopharma	-$2.19	-$2.33	-$0.14	-$2.33	$11.96 million	$9.84 million
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.17	1.89	2.47
STRO Sutro Biopharma	N/A	3.32	3.32
TELO Telomir Pharmaceuticals	N/A	16.16	16.16
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
STRO Sutro Biopharma	96.99%
TELO Telomir Pharmaceuticals	N/A
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
STRO Sutro Biopharma	1.80%
TELO Telomir Pharmaceuticals	16.36%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	61	72.33 million	64.95 million	Optionable
STRO Sutro Biopharma	128	16.58 million	16.28 million	Optionable
TELO Telomir Pharmaceuticals	5	73.68 million	57.52 million	N/A
VOR Vor Biopharma	76	59.16 million	59.00 million	Optionable

TELO, VOR, ABOS, and STRO Headlines

Recent News About These Companies

Vor Biopharma Q3 Loss Narrows

October 30 at 2:17 PM | finance.yahoo.com

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

October 30 at 8:00 AM | globenewswire.com

Vor Biopharma (NASDAQ:VOR) Shares Break Above Fifty Day Moving Average - Here's Why

October 30 at 6:19 AM | marketbeat.com

Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With IgA Nephropathy

October 23, 2026 | marketscreener.comM

Vor Biopharma Inc. (NASDAQ:VOR) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 23, 2026 | americanbankingnews.com

Vor Biopharma Inc. (VOR) - What Are Investment Firms Thinking About This Stock?

October 23, 2026 | marketbeat.com

William Blair Begins Coverage on Vor Biopharma (NASDAQ:VOR)

October 23, 2026 | americanbankingnews.com

Vor Bio says its experimental drug slowed loss of kidney function in late-stage study

October 22, 2026 | reuters.com

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

October 22, 2026 | globenewswire.com

William Blair initiates coverage of Vor Biopharma at outperform

October 21, 2026 | msn.com

William Blair Initiates Vor Biopharma at Outperform

October 21, 2026 | marketscreener.comM

Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at William Blair

October 21, 2026 | marketbeat.com

Wells Fargo Keeps Their Buy Rating on Vor Biopharma (VOR)

October 19, 2026 | theglobeandmail.com

Vor Biopharma (NASDAQ:VOR) Upgraded to Strong-Buy at Citigroup

October 17, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Shares Climb 7.2% - Time to Buy?

October 15, 2026 | marketbeat.com

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

October 9, 2026 | uk.finance.yahoo.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026 | globenewswire.com

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

October 4, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

September 30, 2026 | marketbeat.com

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | finanznachrichten.de

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TELO, VOR, ABOS, and STRO Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$0.21 -2.08 (-90.83%)

Closing price 04:00 PM Eastern

Extended Trading

$0.22 +0.01 (+5.71%)

As of 07:59 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Sutro Biopharma NASDAQ:STRO

$9.10 -0.04 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 0.00 (0.00%)

As of 07:30 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Telomir Pharmaceuticals NASDAQ:TELO

$0.94 -0.03 (-3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 +0.00 (+0.09%)

As of 07:32 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Vor Biopharma NASDAQ:VOR

$19.68 -1.23 (-5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$19.73 +0.05 (+0.27%)

As of 07:56 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, VOR, ABOS, and STRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, VOR, ABOS, and STRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, VOR, ABOS, and STRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TELO, VOR, ABOS, and STRO Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Sutro Biopharma NASDAQ:STRO

Telomir Pharmaceuticals NASDAQ:TELO

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, VOR, ABOS, and STRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, VOR, ABOS, and STRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, VOR, ABOS, and STRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TELO, VOR, ABOS, and STRO Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Sutro Biopharma NASDAQ:STRO

Telomir Pharmaceuticals NASDAQ:TELO

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools